Use of selective serotonin 5-HT1A receptor agonists for treating side-effects of VMAT inhibitors
US11191758B2 · kind B2 · utility
0Cited by
0References
6Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 20, 2018 |
| Grant date | Dec 7, 2021 |
| Priority date | — |
| Expiry date | Aug 18, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the reduction of the side-effects induced by tetrabenazine or other inhibitors of vesicular monoamine transporter (VMAT), in the treatment of central nervous system disorders such as Huntington's disease, L-DOPA-induced dyskinesias in Parkinson's disease, Tourette's syndrome or tardive dyskinesia. The invention comprises administering to a patient in need thereof an effective amount of activates selective serotonin 5-HT1A receptors agonist, whereby the side-effects of depression or Parkinsonism induced by tetrabenazine or other VMAT inhibitors are minimized.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.